Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. (Q54263472)
Jump to navigation
Jump to search
scientific article published on 2 March 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. |
scientific article published on 2 March 2018 |
Statements
1 reference
Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. (English)
1 reference
S Bourgeois
H Van Vlierberghe
T Sersté
S Francque
P Michielsen
D Sprengers
H Reynaert
J Henrion
S Negrin Dastis
J Delwaide
L Lasser
J Decaestecker
H Orlent
F Janssens
G Robaeys
I Colle
P Stärkel
C Moreno
F Nevens
T Vanwolleghem
Belgian NA Stop Study Group
2 March 2018
1 reference
1 reference
1 reference
1 reference